Novartis presented new Pluvicto(lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2025…. read more.
Novartis announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta (iptacopan) in adults living with IgA nephropathy (IgAN). Fabhalta, an oral alternative complement pathway inhibitor,… read more.
Precigen Inc. announced long-term follow-up data demonstrating durable responses to Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). These data were presented at… read more.
AbbVie announced the FDA approval of a supplemental new drug application (sNDA) that updates the indication statement for Rinvoq (upadacitinib) for the treatment of adults with moderately to… read more.
Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced that a presentation related to Peyronie’s disease, or PD, and Xiaflex (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will… read more.
MannKind Corporation announced that the FDA has accepted the supplemental biologics license application (sBLA) seeking approval for Afrezza (insulin human) Inhalation Powder in children and adolescents living with… read more.
New data from Eli Lilly and Company showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 (IL-23p19) to help patients with moderately to severely active ulcerative colitis (UC)… read more.
Inspire Medical Systems Inc. published Inspire V clinical outcomes data from its Singapore clinical study as well as the Company’s limited market release in the United States including… read more.
Jascayd (nerandomilast) tablets has been approved by the FDA as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients. Jascayd is the first and only… read more.
Medtronic announced the results from the Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial now published in the distinguished Journal of the American Medical… read more.
Johnson & Johnson announced new 48-week data from the Phase III ASTRO study evaluating Tremfya (guselkumab) subcutaneous (SC) induction and maintenance therapy in adults with moderately to severely… read more.
Regeneron Pharmaceuticals, Inc. announced that the FDA has approved Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the treatment of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
